Related Experiment Video
Updated: Jun 16, 2026
14:20
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
A Biomimetic Dual-Targeting Nano-APA-Editor Reprograms the 3'UTR Landscape for Tongue Squamous Cell Carcinoma Therapy
1State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Hubei Key Laboratory of Stomatology, Key Laboratory of Oral Biomedicine Ministry of Education, School & Hospital of Stomatology, Wuhan University, Wuhan, P. R. China.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|June 15, 2026
Summary
Researchers developed a novel nanoplatform, the Nano-APA-editor, to precisely target and silence NUDT21, a key regulator in oral cancer. This approach restores tumor suppressor function and effectively reduces oral squamous cell carcinoma growth.
Area of Science:
- Oncology
- Molecular Biology
- Nanomedicine
Background:
- Post-transcriptional regulation, specifically alternative polyadenylation (APA), is increasingly recognized as crucial in cancer development.
- Dysregulation of APA by NUDT21 promotes oral squamous cell carcinoma (OSCC) by creating translationally repressed, long 3'UTR isoforms of tumor suppressors like PTEN.
- NUDT21 upregulation correlates with poor prognosis and advanced stage in OSCC.
Purpose of the Study:
- To identify NUDT21 as a therapeutic target in OSCC.
- To develop a novel nanoplatform, the Nano-APA-editor, for precise NUDT21 targeting and silencing.
- To evaluate the therapeutic efficacy and safety of the Nano-APA-editor in OSCC models.
Main Methods:
- Design and synthesis of the Nano-APA-editor, incorporating an HMSN core, sgRNA-NUDT21 payload, and a dual-targeting strategy (DC membrane and TA-aptamer).
- In vitro assessment of NUDT21 silencing, 3'UTR isoform switching, PTEN restoration, and inhibition of malignant phenotypes.
- In vivo evaluation in an orthotopic OSCC model, comparing Nano-APA-editor efficacy and biocompatibility against paclitaxel (PTX).
- Confirmation of target engagement and functional restoration via in vivo molecular analysis.
Main Results:
- The Nano-APA-editor selectively silenced NUDT21, inducing a shift towards short 3'UTR isoforms and restoring PTEN and other tumor suppressors.
- In vitro studies demonstrated inhibition of malignant phenotypes.
- In vivo studies showed significant tumor regression in OSCC models, surpassing PTX efficacy with good biocompatibility.
- Confirmed NUDT21 downregulation and restoration of PTEN, WEE1, and TGF-β signaling in vivo.
Conclusions:
- NUDT21 is a critical therapeutic target in OSCC, driving malignant phenotypes through APA.
- The Nano-APA-editor represents a viable nanoplatform for precision gene therapy by re-engineering the APA switch.
- This 'post-transcriptional re-engineering' strategy offers a powerful and safe therapeutic modality for OSCC and potentially other cancers.
